Latest Chemotherapeutic agents Stories
CALGARY, Nov. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
SEATTLE, Nov. 18, 2010 /PRNewswire/ -- Cell Therapeutics, Inc.
Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought.
Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism.
EMERYVILLE, Calif., Nov. 10, 2010 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, 2010 at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time).
EMERYVILLE, Calif., Nov. 4, 2010 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Credit Suisse 2010 Healthcare Conference on Thursday, November 11, 2010 at 9:00 a.m. Mountain Time (8:00 a.m.
MANHATTAN BEACH, Calif., Nov. 4, 2010 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that the European Patent Office (EPO) has issued EPO Patent Grant No.
A UC Irvine oncologistâ€™s work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer.
SEATTLE, Nov. 1, 2010 /PRNewswire/ -- Cell Therapeutics, Inc.
EMERYVILLE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
- To swell, as grain or wood with water.